العديد من الإنجازات العلمية في مجال معالجة بعض الأمراض السرطانية في سنة ٢٠١٤ Countless advances in cancer field in 2014. Some examples: Pertuzumab: excellent response rate in the preoperative setting and around median 15 months extra to the original survival in Her2 positive metastatic breast cancer Obinutizumab: anti CD20 antibody is a new very promising option for elderly CLL and some low grade lymphomas, now being studied in other Non Hodgkins Lymohoma. May take over Rituximab Ramucirumab: new option for metastatic gastric and GE junction cancers, with statistically significant benefits Docetaxel: can be added to certain newly diagnosed metastatic prostate cancer, adds median 12 months extra survival Enzalutimide: another oral option for metastatic prostate cancer can now be considered first line Ibrutinib and Idelalisib: continue to emerge as new options for chronic lymphocytic leukemia and certain other low grade lymphomas, and future other NHL Continuous better outcomes and available options for metastatic melanoma; Utilizing targeted and immunotherapy options Panitumumab Plus FOLFOX: first line option in Wild-Type KRAS Metastatic Colorectal Cancer Chest Radiation Improves Survival in Extended-Stage Small Cell Lung Cancer Decent better response rate and improve survival in adding bevacizumab to chemotherapy for cervical cancer Apixaban: new good oral option to treat deep venous thrombosis and pulmonary embolism, in addition to its old indications Positive early studies in Anti-PD1 therapy, coming for solid tumors Positive signs for coming advances in Acute Lymphoblastic Leukemia using BiTEs therapies Updated Recommendations for Evaluation, Staging, and Response Assessment for Hodgkin and Non-Hodgkin Lymphomas, with less need for Followup scans And more .. Yet cancer is still one of the major causes of morbidity and mortality, way to come in the future ..
Posted on: Sat, 08 Nov 2014 21:40:03 +0000
Trending Topics
Recently Viewed Topics
© 2015